» Articles » PMID: 36674280

Should I Stay or Should I Go? A Qualitative Exploration of Stigma and Other Factors Influencing Opioid Agonist Treatment Journeys

Overview
Publisher MDPI
Date 2023 Jan 21
PMID 36674280
Authors
Affiliations
Soon will be listed here.
Abstract

(1) The harm-reduction benefits of opioid agonist treatment (OAT) are well-established; however, the UK government's emphasis on "recovery" may be contributing to a high proportion of people leaving treatment and low retention rates. We wanted to develop a rich and nuanced understanding of the factors that might influence the treatment journeys of people who use OAT. (2) We explored factors at each level of the socioecological system and considered the ways these interact to influence treatment journeys in OAT. We carried out semi-structured interviews with people who use OAT (n = 12) and service providers (n = 13) and analysed data using reflexive thematic analysis. (3) We developed three themes representing participant perceptions of treatment journeys in OAT. These were: (1) The System is Broken; (2) Power Struggles; and (3) Filling the Void. (4) Conclusions: The data suggest that prioritisation of treatment retention is important to preserve the harm-reduction benefits of OAT. Stigma is a systemic issue which presents multiple barriers to people who use OAT living fulfilling lives. There is an urgent need to develop targeted interventions to address stigma towards people who use OAT.

Citing Articles

The Relationship Between Methadone and Buprenorphine Enrollment and Overdose Prevention and Treatment Behaviors Among a Community Sample of People Who Use Opioids in Baltimore, Maryland.

Latkin C, Dayton L, Davey-Rothwell M, Jones A Int J Environ Res Public Health. 2025; 22(2).

PMID: 40003439 PMC: 11855099. DOI: 10.3390/ijerph22020213.


Giving Up the Guidelines: A Qualitative Evaluation of Disrupted Prescribing of Opioid Substitution Therapy in a Rural UK County During and Following the COVID-19 Pandemic.

Lewington T, Burch D, Petitjean G Int J Environ Res Public Health. 2025; 21(12.

PMID: 39767446 PMC: 11675789. DOI: 10.3390/ijerph21121605.


"It's a delicate balance": clinicians' experiences of providing heroin-assisted treatment.

Ellefsen R, De Pirro S, Haukland V, Wusthoff L, Arnevik E Harm Reduct J. 2024; 21(1):230.

PMID: 39741328 PMC: 11687196. DOI: 10.1186/s12954-024-01135-2.


Supervised on-site dosing in injectable opioid agonist treatment-considering the patient perspective. Findings from a cross-sectional interview study in two German cities.

Friedmann Z, Kinkel H, Kuhner C, Zsolnai A, Mick I, Binder A Harm Reduct J. 2023; 20(1):162.

PMID: 37915058 PMC: 10619267. DOI: 10.1186/s12954-023-00896-6.


Stigmatized attitudes of medical staff toward people who use drugs and their determinants in Japanese medical facilities specialized in addiction treatment.

Katayama M, Fujishiro S, Sugiura K, Konishi J, Inada K, Shirakawa N Neuropsychopharmacol Rep. 2023; 43(4):576-586.

PMID: 37814500 PMC: 10739075. DOI: 10.1002/npr2.12380.


References
1.
Frank D, Mateu-Gelabert P, Perlman D, Walters S, Curran L, Guarino H . "It's like 'liquid handcuffs": The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients' lives. Harm Reduct J. 2021; 18(1):88. PMC: 8364307. DOI: 10.1186/s12954-021-00535-y. View

2.
Ford C, Nutt D, Eastwood N, Gold D, Jolly J, Murphy F . Is the UK's 2017 drug strategy fit for purpose?. BMJ. 2017; 358:j4405. DOI: 10.1136/bmj.j4405. View

3.
MacArthur G, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J . Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012; 345:e5945. PMC: 3489107. DOI: 10.1136/bmj.e5945. View

4.
McLeroy K, BIBEAU D, Steckler A, Glanz K . An ecological perspective on health promotion programs. Health Educ Q. 1988; 15(4):351-77. DOI: 10.1177/109019818801500401. View

5.
Earnshaw V, Smith L, Chaudoir S, Amico K, Copenhaver M . HIV stigma mechanisms and well-being among PLWH: a test of the HIV stigma framework. AIDS Behav. 2013; 17(5):1785-95. PMC: 3664141. DOI: 10.1007/s10461-013-0437-9. View